SCHOTT Pharma Aktie
| 19,40EUR | 0,10EUR | 0,52% |
WKN DE: A3ENQ5 / ISIN: DE000A3ENQ51
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 4 145 | 4 528 | 4 683 | 4 646 | 4 689 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,14 | 0,14 | 0,18 | 0,19 | 0,20 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 239 | 302 | 555 | 468 | 589 |
| Summe Anlagevermögen | 369 | 448 | 657 | 778 | 888 |
| Summe Aktiva | 608 | 750 | 1 211 | 1 246 | 1 477 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 292 | 330 | 502 | 554 | 685 |
| Summe Eigenkapital | 316 | 419 | 709 | 692 | 792 |
| Summe Passiva | 608 | 750 | 1 211 | 1 246 | 1 477 |
Adresse
| Hattenbergstrasse 10, 55122 Mainz | |
| Telefon | +49 (6131) 66-0 |
| Internet | https://www.schott.com |
Management
|
Andreas Reisse
Chairman-Management Board & CEO |
|
Ann-Kristin Erkens
Member-Supervisory Board |
|
Christine Wening
Member-Supervisory Board |
|
Eva Kienle
Member-Supervisory Board |
|
Mario Just
Member-Supervisory Board |
|
Peter Goldschmidt
Chairman-Supervisory Board |
|
Reinhard Mayer
Chief Financial Officer |
|
Tobias Erfurth
Head-Investor Relations |
|
Wolfgang Wienand
Deputy Chairman-Supervisory Board |